Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Cemiplimab mit Chemotherapie und Immuntherapie bei Menschen mit Kopf- und Halskrebs

17. November 2026 aktualisiert von: Memorial Sloan Kettering Cancer Center

Eine Pilotstudie zu neoadjuvantem Cemiplimab mit Platin-Doppel-Chemotherapie und Cetuximab bei Patienten mit resezierbarem, lokal fortgeschrittenem Kopf-Hals-Plattenepithelkarzinom

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • New Jersey
      • Basking Ridge, New Jersey, Vereinigte Staaten, 07920
        • Rekrutierung
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • Kontakt:
      • Middletown, New Jersey, Vereinigte Staaten, 07748
        • Rekrutierung
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Kontakt:
          • Lara Dunn, MD
          • Telefonnummer: 646-608-3787
      • Montvale, New Jersey, Vereinigte Staaten, 07645
        • Rekrutierung
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Kontakt:
          • Lara Dunn, MD
          • Telefonnummer: 646-608-3787
    • New York
      • Commack, New York, Vereinigte Staaten, 11725
        • Rekrutierung
        • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
        • Kontakt:
          • Laura Dunn, MD
          • Telefonnummer: 646-608-3787
      • Harrison, New York, Vereinigte Staaten, 10604
        • Rekrutierung
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • Kontakt:
          • Lara Dunn, MD
          • Telefonnummer: 646-608-3787
      • New York, New York, Vereinigte Staaten, 10065
        • Rekrutierung
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
          • Lara Dunn, MD
          • Telefonnummer: 646-608-3787
      • Rockville Centre, New York, Vereinigte Staaten, 11553
        • Rekrutierung
        • Memorial Sloan Kettering Nassau (Limited Protocol Activites)
        • Kontakt:
          • Laura Dunn, MD
          • Telefonnummer: 646-608-3787

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck that has arisen from the oral cavity, oropharynx, nasal cavity, paranasal sinuses, larynx, or hypopharynx

  • Clinical stage T1, N2-3; T2, N1-3, T3/T4a, Any N (AJCC, 8th ed.) without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis, for which standard-of-care treatment would entail surgical resection with adjuvant radiation +/- chemotherapy.

    ° Patients with recurrent and multiple primary head and neck cancers that are surgically resectable are eligible if the patient did not receive prior radiation or systemic therapy.

  • Disease must be amenable to surgical resection.

  • The patient must be a surgical candidate.

  • Adequate organ and bone marrow function documented by:

    1. Hemoglobin > 9.0 g/dL
    2. Absolute neutrophil count (ANC) >1.5 x 10^9/L
    3. Platelet count >100 x 10^9/L
    4. Serum creatinine <1.5 upper limit of normal (ULN) or estimated creatinine clearance (CrCl) >30 mL/min
    5. Adequate hepatic function:
  • Total bilirubin <1.5 x upper limit of normal ULN)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 3 x ULN

  • Alkaline phosphatase (ALP) <2.5 x ULN Note: For patients with Gilbert syndrome, total bilirubin <3x ULN. Upper central must be documented appropriately as past medical history.

  • Men and woman >18 years old

  • Eastern cooperative oncology group performance status < 1 CPS ≥ 20 and

Inclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:

  • Pathologically (histologically) proven diagnosis of oral cavity squamous cell carcinoma HPV-negative by p16 or ISH
  • Clinical Stage will be limited to cT2 with cN0-N2b, cM0 with only 1 lymph node >2.0 cm in the short axis without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis.
  • Curative intent surgical management is determined to require a free flap, mandibulectomy, glossectomy, or other significant surgical morbidity.

Exclusion Criteria:

  • Prior radiation and systemic therapy for a head and neck cancer.
  • Oral cavity cancer that is not amenable to surgical resection or the patient is not a surgical candidate.
  • Active or prior documented autoimmune or inflammatory disorders that have been treated with steroids or immunomodulator therapy in the past 5 years.

Exceptions: Patients with vitiligo, type 1 diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that is resolved, or psoriasis it does not require systemic treatment are permitted.

  • Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressant medications within 14 days of treatment on study.

  • Receipt of live attenuated vaccine within 30 days prior initiating treatment on study.

  • Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.

  • Any infection requiring hospitalization and/or intravenous antibiotic therapy within 2 weeks of the start of treatment.

  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency.

    1. Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection monitoring will be performed per local standards
    2. Patients with HBV (hepatitis B surface antigen positive; HBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months be on the last dose of Cemiplimab.
    3. Patients were HCV antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR, either spontaneously or in response to successful prior course of anti-HCV therapy) are permitted.
  • History of immune-related pneumonitis with the last 5 years.

  • History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of leuko-corticoids to assist with management.

  • Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.

  • Patients with a history of solid organ transplant (exception: corneal transplant)

  • Any medical comorbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that in the opinion of the investigator renders the patient unsuitable for participation in a clinical trial due to high safety risks.

  • Women with a positive serum or urine beta-hCG pregnancy test at screening/baseline visit. If positive, pregnancy must be ruled out by ultrasound for patient to be eligible.

  • Breast-feeding women

  • Women of childbearing potential who are sexually active and aren't willing to practice highly effective contraception prior to the first dose of Cemiplimab, during the study, and for at least 180 days after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined estrogen and progesterone containing hormonal contraception or progesterone and-only hormonal contraception associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening
    2. Intrauterine device; intrauterine hormone-releasing system
    3. Bilateral tubal ligation
    4. Vasectomized partner and/or
    5. Sexual abstinence

Exclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:

  • History of head and neck cancer. This includes patients who present with a recurrence of a previously treated oral cavity squamous cell carcinoma.
  • Synchronous primary squamous cell carcinomas of the oral cavity.
  • Presence of diffuse oral mucosa dysplasia or leukoplakia that per the judgement of the clinical investigator represents a clinically and independent significant risk of developing a second oral cavity primary

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Head and Neck Squamous Cell Cancer/HNSCC

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8

Carboplatin AUC 5 on weeks 2, 5, and 8

Docetaxel 75mg/m2 on weeks 2, 5, and 8

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).

Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of >0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines [2]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.

If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.

Andere Namen:
  • Taxol
Experimental: Secondary Cohort

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

Experimental: Tertiary Cohort: Oral cavity squamous cell carcinoma (OCSCC)

A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC)

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of toxicities graded according to NCI CTCAE
Zeitfenster: 1 year

The primary endpoint is safety and tolerability, which will be evaluated by a description of observed adverse events by grades. All toxicities will be graded according to NCI CTCAE, Version5.0. The regimen will be deemed safe and well tolerated if there are 2 or fewer DLTs out of 10 patients enrolled. A DLT is defined as any non-hematologic grade 3 or greater adverse event as defined by CTCAE v5.0 that is thought to be related to the addition of Cemiplimab to the combination of a platinum-doublet with cetuximab.

1 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Lara Dunn, MD, Memorial Sloan Kettering Cancer Center

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. Januar 2021

Primärer Abschluss (Geschätzt)

20. Juni 2027

Studienabschluss (Geschätzt)

20. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

21. Januar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Januar 2021

Zuerst gepostet (Tatsächlich)

25. Januar 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .